Sutro Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Sutro Biopharma, Inc. (Nasdaq: STRO) on June 18, 2019, covering events occurring on June 18, 2019, and June 21, 2019. The filing addresses significant changes to the Company's Board of Directors under Item 5.02.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and director compensation arrangements.
Material Changes
- Resignation: Daniel Janney resigned from the Board of Directors, including his roles as Chair of the Board, and member of the Compensation and Nominating and Governance Committees, effective June 24, 2019. The resignation was not due to any disagreement with the Company.
- Appointment: Connie Matsui was appointed as a Class II director, Chair of the Board, Chair of the Nominating and Governance Committee, and member of the Compensation Committee, effective June 24, 2019.
Compensation and Governance Details
In connection with her appointment, Ms. Matsui will receive pro rata portions of the following annual retainers for the remainder of the year:
- Director Retainer: $35,000
- Chair of the Board Retainer: $35,000
- Chair of Nominating and Governance Committee Retainer: $10,000
- Compensation Committee Member Retainer: $5,000
Additionally, the Board granted Ms. Matsui a stock option to purchase 23,076 shares of common stock. The exercise price is set at the closing sale price on June 24, 2019, with monthly vesting over three years contingent on continued service. An indemnification agreement was also executed.
Outlook and Risks
The filing does not contain management commentary on business outlook, risks, contingencies, or unusual items beyond the standard disclosure of the director transition.
Key Facts for Investor Verification
- Confirm the effective date of the Board composition change (June 24, 2019).
- Verify the total pro rata cash compensation awarded to the new Chair and Director for the remainder of 2019.
- Review the vesting schedule and exercise price of the 23,076 stock options granted to Ms. Matsui.
- Check subsequent filings for any further changes to the Board or executive leadership.